Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

Expansion of GPIIB/IIIA inhibitors drug product range: A methodological approach

Pyatigorskaya N. V., Brkich G. E`., Beregovy'kh V. V., Gammel` I. V., Veretennikov E. A.
Journal of Pharmaceutical Sciences and Research
Vol.9, Issue11, P. 2311-2314
Опубликовано: 2017
Тип ресурса: Статья
Аннотация:
Integrin complex GPIIB/IIIA found on platelets plays an important role in thrombogenesis and is a key component of platelet aggregation process. Currently, few inhibitors of GPIIb/IIIa platelet receptors with limited indications and several side effects are used in clinical practice for depression of platelet aggregation. Present study is devoted to development of scientific and methodological approach to expansion of GPIIb/IIIa inhibitors drug product range by means of information analysis methods. Use of peptide compounds as platelet glycoprotein IIb/IIIa inhibitors appears to be most promising. Systematic analysis of natural and synthetic peptide GPIIb/IIIa inhibitors nomenclature allows authors to express modern view on the problem of pharmaceutical development of novel antiplatelet drug products. The authors conclude, that modern approach to pharmaceutical development of peptide antiplatelet drugs for GPIIb/IIIa inhibition should be based on advanced methods, i.e. computer drug de
Ключевые слова:
Antiaggregants; Antiplatelet drugs; Novel drug discovery; Peptide therapeutics; Platelet glycoprotein IIB/IIIA inhibitors
fibrinogen receptor; fibronectin; integrin receptor; protein inhibitor; receptor; vitronectin; von Willebrand factor; acute coronary syndrome; amino acid sequence; antigenicity; Article; chemical structure; coronary artery disease; enzyme activity; human; protein expression; receptor affinity; thrombocyte aggregation
Язык текста: Английский
ISSN: 0975-1459
Pyatigorskaya N. V. Natal`ya Valeryevna 1965-
Brkich G. E`. Galina E`duardovna 1967-
Beregovy'kh V. V. Valerij Vasilyevich 1942-
Gammel` I. V. Irina Vladimirovna 1964-
Veretennikov E. A. Evgenij Aleksandrovich 1964-
Пятигорская Н. В. Наталья Валерьевна 1965-
Бркич Г. Э. Галина Эдуардовна 1967-
Береговых В. В. Валерий Васильевич 1942-
Гаммель И. В. Ирина Владимировна 1964-
Веретенников Е. А. Евгений Александрович 1964-
Expansion of GPIIB/IIIA inhibitors drug product range: A methodological approach
Текст визуальный непосредственный
Journal of Pharmaceutical Sciences and Research
Vol.9, Issue11 P. 2311-2314
2017
Статья
Antiaggregants Antiplatelet drugs Novel drug discovery Peptide therapeutics Platelet glycoprotein IIB/IIIA inhibitors
fibrinogen receptor fibronectin integrin receptor protein inhibitor receptor vitronectin von Willebrand factor acute coronary syndrome amino acid sequence antigenicity Article chemical structure coronary artery disease enzyme activity human protein expression receptor affinity thrombocyte aggregation
Integrin complex GPIIB/IIIA found on platelets plays an important role in thrombogenesis and is a key component of platelet aggregation process. Currently, few inhibitors of GPIIb/IIIa platelet receptors with limited indications and several side effects are used in clinical practice for depression of platelet aggregation. Present study is devoted to development of scientific and methodological approach to expansion of GPIIb/IIIa inhibitors drug product range by means of information analysis methods. Use of peptide compounds as platelet glycoprotein IIb/IIIa inhibitors appears to be most promising. Systematic analysis of natural and synthetic peptide GPIIb/IIIa inhibitors nomenclature allows authors to express modern view on the problem of pharmaceutical development of novel antiplatelet drug products. The authors conclude, that modern approach to pharmaceutical development of peptide antiplatelet drugs for GPIIb/IIIa inhibition should be based on advanced methods, i.e. computer drug de